We have several clinical programs that can be accessed through referral:
- HPV infection (genital warts and dysplasia)
- Mental Health and neuro-cognitive problems
- Aging & Metabolic syndromes (diabetes, dyslipidemia)
- Addictions care & case management
- Hemato-oncology and cancer chemotherapy
- Hepatic steatosis and Fibroscan
- Therapeutic Drug Monitoring
Referral for assessment and treatment of HIV or hepatitis C infection
Physicians are welcome to contact the CVIS to refer a patient for evaluation or treatment of a patient. The contact numbers are:
CVIS – Glen site 514 843-2090
CVIS – Glen site (Fax) 514 843-2092
MUHC telephone operator 514 934-1934 (Locating ext 53333)
HIV consultation service (1-800 line for HIV-related medical questions)
Healthcare professionals can also contact us by telephone and by email to obtain information or resources about diagnosing, treating, and leaning more about HIV and HCV infections.
By telephone: 1-800 363 4814 (or 514 849 5520 in Montreal). This is the fastest way to contact us, especially in emergency situations such as when a healthcare worker or patient may have been exposed accidentally to HIV or HCV. A nurse will answer your call immediately during working hours (Monday-Friday; 08h00-17h00). After 17h00, you will leave a message on a voice-mail and a physician will call you back and provide advice. After hours service is offered for medical emergency situations only (post-exposure prophylaxis or medical consultation). Email enquiries cannot be answered after outside working hours (08h00-17h00).
Non-invasive diagnostic center for liver fibrosis and fatty liver
Dr Sebastiani has developed a diagnostic center for non-invasive detection of hepatic fibrosis and steatosis at McGill University, using a Fibroscan/Controlled attenuation parameter (CAP). In this new center, we have set up a referral program in Quebec, where specialists of infectious diseases/gastroenterologists/hepatologists/specialist in internal medicine and family physicians who treat patients with hepatic steatosis, HCV, HBV, HIV can refer patients for screening of liver fibrosis, and hepatic steatosis.
Nowadays, fatty liver is the most common liver disease in Canadians, affecting 25% of the general population. In people living with HIV, fatty liver is much more frequent, with a prevalence of up to 55%. Fatty liver can lead to cirrhosis and hepatocellular carcinoma.
In hepatitis C and B, liver fibrosis stage is pivotal for decision on antiviral treatment and management, as patients with advanced fibrosis require screening for hepatocellular carcinoma and esophageal varices. In the past, the only way to diagnose fatty liver and hepatic fibrosis was to undergo a liver biopsy, which can be painful and has risks.
Québec Antiretroviral Therapeutic Drug Monitoring Program
Therapeutic drug monitoring (TDM) is the practice of measuring drug concentrations in the blood and adjusting medication doses as needed. This allows individualization of drug doses according to its concentrations.
The program offers its services throughout Canada and the United States. Antiretroviral TDM for Québec residents is entirely funded by the Ministère de la Santé et des Services sociaux du Québec. For more information on the service, please go to our website at: https://muhc.ca/quebec_tdm
If you have any questions, you may contact a pharmacist from Monday to Friday, 9:00 AM to 4:00 PM ET at: 514-934-1934 ext 32168.